Filing Flows

Filing Flows › Companies › Cardiff Oncology › Cash flow

Cardiff Oncology cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$11.8M in Q2 2026 · −$40.9M over twelve months

Operating cash flow−$11.8M
Free cash flow−$11.8M

Analysis

In Q2 2026, Cardiff Oncology generated −$11.8M of operating cash flow. That is $3.4M less than in Q2 2025 (−$8.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$40.9M; the largest uses were operating cash flow ($40.9M), capital spending ($62K); besides operations, cash came from other investing ($36.5M), other financing ($2.0M); the cash balance fell by $1.6M.

Operating cash flow was −$11.8M against net income of −$9.2M. The largest differences: payables −$3.5M, stock-based pay +$920K, depreciation & amortization +$87K.

Free cash flow

Cardiff Oncology: free cash flow by quarterCardiff Oncology: free cash flow by quarter−$10.5MQ3 2024−$10.3MQ4 2024−$12.8MQ1 2025−$8.3MQ2 2025−$10.9MQ3 2025−$6.0MQ4 2025−$12.3MQ1 2026−$11.8MQ2 2026
Operating cash flow less capital spending.
Cardiff Oncology: operating cash flow against capital spendingCardiff Oncology: operating cash flow against capital spendingOperating cash flowCapital spending−$10.5M$0Q3 2024−$10.3M$0Q4 2024−$12.8M$0Q1 2025−$8.3M$0Q2 2025−$10.8M$18KQ3 2025−$6.0M$0Q4 2025−$12.3M$0Q1 2026−$11.8M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$11.8M, Capital spending $0.

Capital allocation, year by year

Cardiff Oncology: where the cash came from (up) and went (down), by fiscal yearCardiff Oncology: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$23.0MFY2021: Shares issued $34.2MFY2021: Capital spending −$205K$34.2MFY2021FY2022: Operating cash flow −$33.8MFY2022: Shares issued $75KFY2022: Capital spending −$1.0M$75KFY2022FY2023: Operating cash flow −$30.9MFY2023: Capital spending −$582KFY2023FY2024: Operating cash flow −$37.7MFY2024: Shares issued $53.8MFY2024: Capital spending −$80K$53.8MFY2024FY2025: Operating cash flow −$37.9MFY2025: Shares issued $493KFY2025: Capital spending −$44K$493KFY2025
Over these 5 years operating cash flow totalled −$163M; the largest uses were operating cash flow ($163M) and capital spending ($1.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$34.5M
Debtnone
Net cash$34.5M
Cash runway10 months

Cardiff Oncology is burning cash: its operations consume cash, a free cash flow of −$40.9M a year at the current rate against $34.5M of cash and investments: a runway of about 10 months before any new financing.

Where the cash came from and went

Cardiff Oncology: sources (+) and uses (−) of cash, Q2 2026Cardiff Oncology: sources (+) and uses (−) of cash, Q2 2026Other investing$12.3MOperating cash flow−$11.8MCash drawn (+) / kept (−)−$653KOther financing$148KShares issued$1K
Cardiff Oncology: sources (+) and uses (−) of cash, TTM to Q2 2026Cardiff Oncology: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$40.9MOther investing$36.5MOther financing$2.0MCash drawn (+) / kept (−)$1.6MShares issued$808KCapital spending−$62K

From profit to cash

Cardiff Oncology: net income to operating cash flow, Q2 2026Cardiff Oncology: net income to operating cash flow, Q2 2026Net income−$9.2MDepreciation & amortization$87KStock-based pay$920KReceivables$2KPayables−$3.5MPrepaid and other assets−$83KOperating cash flow−$11.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$11.8M—$1K−$653K−$11.8M
Q1 2026−$12.3M—$105K$8.9M−$12.3M
Q4 2025−$6.0M—$465K−$7.3M−$6.0M
Q3 2025−$10.8M−$18K$25K$649K−$10.9M
Q2 2025−$8.3M——$13.3M−$8.3M
Q1 2025−$12.8M—$3K$27.4M−$12.8M
Q4 2024−$10.3M—$44.2M−$38.4M−$10.3M
Q3 2024−$10.5M—$7.4M$12.5M−$10.5M

Cardiff Oncology: income statement and cash flow

Cardiff Oncology, Q2 2026: revenue $104K (-14% year over year). The chart follows the revenue to costs, profit and cash.

Cardiff Oncology: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.